3D graphic of CAR NK cells killing a cancer cell
3D graphic of CAR NK cells killing a cancer cell
Logo

Gene-modified cells

The therapeutic potential of genetically modified cells is already huge - and yet it’s waiting to be explored. With our cutting-edge technologies we help you to develop solutions from early discovery to large-scale cell manufacturing.

Choose your topic of interest

CAR T cells

Microscopic image showing a CAR T cell killing a cancer cell

CAR T cell research solutions

Our solutions enable you to isolate donor T cells and to achieve efficient T cell activation, gene transfer, and expansion. Furthermore, we offer instruments, reagents, and software for functional characterization of rare CAR T cell populations.

Microscopic image showing a CAR T cell killing a cancer cell

Clinical-grade TCR engineered T cell and CAR T cell manufacturing via viral transduction

Automate and standardize your T cell manufacturing process and safeguard your cells in a closed system setup. The CliniMACS Prodigy® T cell Transduction (TCT) and CliniMACS Prodigy T Cell Transduction – Large Scale (TCT-LS) processes integrate all steps from cell isolation, activation, and transduction to expansion and harvest of your final cell product.

CAR NK cells

Microscopic image of CAR NK cells killing a cancer cell

CAR NK cell engineering for research

With our advanced technologies for each workflow step, we at Miltenyi Biotec support CAR NK cell research and therapeutic development. Starting with enrichment of a well-defined NK cell population, we further offer optimized solutions for activation, transduction, expansion, and finally the analysis and phenotyping of engineered CAR NK cells.

Clinical-grade CAR-engineered NK cells via viral transduction

Automate your CAR NK cell manufacturing process and standardize your workflow. Manufacture your cells in a closed and software-controlled environment. The CliniMACS Prodigy® NK Cell Transduction (NKCT) Process integrates all manufacturing steps from cell selection, activation, and transduction to expansion and harvest of your final cell product.

CliniMACS Cell Factory for cell manufacturing showing several CliniMACS Prodigy instruments in rows

Natural killer cells for immunotherapy

Clinical-grade natural killer (NK) cell isolation can be enabled in a two-step, fully automated manner within a closed system on the CliniMACS Prodigy. Additionally, it is possible to use the CliniMACS Prodigy for NK cell expansion or generation of engineered NK cells.

Gamma delta (γδ) T cells

NK Cells MU

Clinical-grade gamma delta (γδ) T cell manufacturing for immunotherapy

The CliniMACS Prodigy® Platform enables the automated manufacturing of γδ T cells. All processing steps – from efficient γδ T cell enrichment, activation, and expansion to optional engineering by viral transduction and final product harvest – are carried out in a closed system. The result is a robust and simplified workflow that facilitates the development of novel γδ T cell therapies.

HSCs

3D graphic showing human hematopoietic stem cells originating from bone marrow

Manufacturing of gene-engineered hematopoietic stem cells

The CliniMACS Prodigy Hematopoietic Stem Cell Engineering (HSCE) process automates manufacturing of gene-engineered hematopoietic stem cells (HSCs) by viral transduction of CD34+ cells. Manufacturing takes place in sterile and single-use tubing sets connected to the CliniMACS Prodigy Instrument, providing a functionally closed system. Its robust performance reduces donor variations while the flexible software allows for easy conversion of manual processes.

Allogeneic cell therapies

3D image of immune cells and DNA helixes

Enabling allogeneic cell therapy manufacturing

At Miltenyi Biotec, we support the entire spectrum of cell therapy modalities, empowering both autologous and allogeneic approaches whether in clinical research or commercial settings.

Our CliniMACS® Instruments, consumables, and reagents provide essential tools needed to achieve optimal growth conditions and create streamlined scalable allogeneic workflows. With flexibility built in, you can seamlessly integrate external expansion systems, such as bioreactors, to meet diverse manufacturing needs. This adaptability makes it easier to advance modalities like allogeneic stem cell therapy or allogeneic CAR T cell therapy.